(MDT:New York Consolidated)
Transactions by MEDTRONIC PLC (MDT) in the last 6 months
St. Jude Medical Inc. (NYSE:STJ) agreed to acquire remaining stake in Spinal Modulation, Inc. from De Novo Ventures, InCube Ventures, LLC, Johnson & Johnson Innovation - JJDC, Inc., Kleiner Perkins Caufield & Byers, Raffles Venture Partners, Medtronic plc (NYSE:MDT), MedVenture Associates V, L.P., managed by MedVenture Associates, The Angels' Forum LLC, The Halo Funds and others for approximately $180 million on April 20, 2015. St. Jude Medical will also make additional ...
DFJ ePlanet Ventures, L.P.
Draper Fisher Jurvetson
InCube Ventures, LLC
Johnson & Johnson Innovation - JJDC, Inc.
Kleiner Perkins Caufield & Byers
MedVenture Associates V, L.P.
Raffles Venture Partners
The Angels' Forum LLC
The Halo Funds
DreaMed Diabete announced that it has received $2 million in an equity round of funding from new investor Medtronic plc on April 6, 2015.
Medtronic plc (NYSE:MDT) acquired Diabeter on April 2, 2015. Amanda Sheldon acted as the public relation advisor and Jeff Warren acted as the investor relation advisor in this transaction.
Medtronic plc (NYSE:MDT) acquired Sophono, Inc. on March 26, 2015. The transaction enables Medtronic's Ear Nose and Throat business to continue its focus on novel therapies and innovative technology solutions and supports Medtronic's therapy innovation strategy. Medtronic will include revenue from the Sophono product line as part of the Surgical Technologies division within the Restorative Therapies Group segment. The transaction is expected to meet Medtronic's long-term ...
Colorado Institute for Drug, Device & Diagnostic Development
Wexford Capital LLC
Wexford Capital, LLC, Private Equity Arm
Semma Therapeutics announced that it has received $44,000,000 in its series A round of funding led by new investor, MPM Capital on March 18, 2015. The transaction included participation from new investors, Arch Venture Partners, L.P., Fidelity Biosciences, and Medtronic plc. The company issued series A preferred stock in the transaction. As a part of the transaction, Robert Millman, Todd Foley, and Jim Scopa of MPM Capital, Steven Knight of Fidelity Biosciences joined ...
Glooko, Inc. announced that it has received $16.5 million in its series B round of funding co-led by new investor, Canaan Partners and Medtronic plc on March 17, 2015. The transaction included participation from existing investors, Samsung Venture Investment Corporation and The Social+Capital Partnership. The company has raised $27.5 million in funding till date. As part of the round, Wende Huttonof Canaan Partners joined the company's board of directors.
Samsung Venture Investment Corporation
The Social+Capital Partnership
|AbbVie Inc||$63.86 USD||-0.82|
|Actavis plc||$285.75 USD||-4.06|
|Amgen Inc||$159.44 USD||-2.67|
|Biogen Inc||$385.80 USD||-0.42|
|Bristol-Myers Squibb Co||$65.03 USD||-0.29|
|View Industry Companies|